Literature DB >> 26471795

[Bevacizumab as first-line therapy in metastatic renal cell carcinoma: Progression-free survival for 3 years].

R Pichler1, W Horninger2, F Aigner3, I Heidegger2.   

Abstract

We report the case of a 72-year-old woman who was diagnosed in 2006 with renal cell cancer (RCC) and had undergone consecutive tumor nephrectomy (clear-cell RCC, Fuhrmann grade II, stage pT3a, R0). Over the years, the patient underwent several surgical and radiological interventions due to various metastatic lesions. This case report describes the 3-year progression-free survival in a patient who underwent first-line therapy with the monoclonal antibody bevacizumab. Except for hypertension, the patient does not suffer currently from any other side effects of bevacizumab therapy.

Entities:  

Keywords:  Hypertension; Metastases resection, sequential; Neoplasm metastasis; Proteinuria; Tumor nephrectomy

Mesh：

Substances：

Year:  2016        PMID： 26471795     DOI： 10.1007/s00120-015-3976-z

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  13 in total

1.  A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.

Authors:  B Melichar; S Bracarda; V Matveev; B Alekseev; S Ivanov; A Zyryanov; R Janciauskiene; E Fernebro; P Mulders; S Osborne; S Jethwa; G Mickisch; M Gore; R J A van Moorselaar; M Staehler; N Magne; J Bellmunt
Journal:  Ann Oncol       Date:  2013-06-26       Impact factor: 32.976

2.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

Authors:  Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Authors:  Bernard Escudier; Joaquim Bellmunt; Sylvie Négrier; Emilio Bajetta; Bohuslav Melichar; Sergio Bracarda; Alain Ravaud; Sophie Golding; Sangeeta Jethwa; Vesna Sneller
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

4.  RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.

Authors:  A Ravaud; C H Barrios; B Alekseev; M-H Tay; S S Agarwala; S Yalcin; C-C Lin; L Roman; M Shkolnik; O Anak; S Gogov; D Pelov; A-L Louveau; B Melichar
Journal:  Ann Oncol       Date:  2015-04-07       Impact factor: 32.976

Review 5.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

6.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

Review 7.  Bevacizumab for patients with metastatic renal cancer: an update.

Authors:  James C Yang
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

8.  Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.

Authors:  Herbert I Hurwitz; Pamela S Douglas; John P Middleton; George W Sledge; David H Johnson; David A Reardon; Dafeng Chen; Oliver Rosen
Journal:  Oncologist       Date:  2013-03-13

9.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Authors:  Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; San-San Ou; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

10.  Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.

Authors:  Jaime Feliu; Antonieta Salud; Maria J Safont; Carlos García-Girón; Jorge Aparicio; Ferran Losa; Carlos Bosch; Pilar Escudero; Enrique Casado; Monica Jorge; Uriel Bohn; Ramon Pérez-Carrión; Alberto Carmona; Ana B Custodio; Joan Maurel
Journal:  PLoS One       Date:  2015-01-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.